Nanobiotix Shares Soar Over 5%, Landing on the SBF 120 Podium

Portzamparc Initiates Buy Rating with a Target of €56, Potential Over 55%

On July 10, Portzamparc released a buy recommendation for Nanobiotix with a target price of €56.00. Compared to the current session price of €35.98, this target represents a theoretical potential of over 55%. By midday, the stock had gained 5.51% and was the second highest riser on the SBF 120, just behind ArcelorMittal.

This position adds to an already strong momentum for the stock, which has risen nearly 25% over the month and gained 668% over the year. During the Q1 2026 report (June 2, 2026), the company highlighted the progress of JNJ-1900 (NBTXR3) and the strengthening of the Nanoprimer platform as opportunity catalysts, while noting the limited progress of the current standard in inoperable non-small cell lung cancer as a risk factor. The analysts' opinions remain a supportive factor for the stock.

Breaking the Resistance at €35.18 Confirms Bullish Resumption

During the session, the stock broke through its resistance at €35.18 and is maintaining above it, at €35.98. The price is now significantly diverging from its 20-day moving average (€31.88, a +12.86% gap) and has moved above its 50-day moving average (€33.64), signaling a bullish resumption after the digestion phase that followed the mid-May record. The gap with the 200-day moving average at €24.36 is nearly 48%, reflecting the annual rally.

The RSI at 58 remains in a neutral zone, not indicating immediate overheating, while the MACD maintains a positive histogram at 0.48. The week's 7.15% gain is part of a broader movement that has seen the stock rise 40% over three months. The next technical threshold identified is at €46.18, the next resistance after today's breakthrough.